Paricalcitol in hemodialysis patients with secondary hyperparathyroidism and its potential benefits

Table 2 Demographics and baseline features of 40 patients

Variable	Patients
Age in yr	49.10 ± 12.86
Sex
Male	23 (57.5%)
Female	17 (42.5%)
Duration in mo of dialysis	55.20 ± 29.32
Weekly dose of paricalcitol in g/wk	12.38 ± 2.77
iPTH in pg/mL	888.84 ± 376.88
ALP in IU/L	133.45 ± 56.86
Blood P in mmol/L	2.16 ± 0. 66
Blood Ca in mmol/L	2.38 ± 0.16
Ca P product in mg2/dL2	63.97 ± 20.30
Hb in g/L	114.82 ± 20.45
Cre in mol/L	807.43 ± 254.64
CRP in mg/L	8.60 ± 16.76

Ca: Calcium; Cre: Creatinine; CRP: C-reactive protein; Hb: Hemoglobin; iPTH: Intact parathyroid hormone; P: Phosphate.